Novartis Pumps $15M Into Israeli Stem Cell Research Firm
The Swiss drug maker Novartis will invest an extra $15 million in Gamida Cell, an Israeli developer of stem cell therapies, Gamida said.
Novartis last year invested $35 million in the company for a 15 percent stake, the Tachles Jewish weekly of Switzerland reported this week. The deal could reach $600 million if Novartis exercises a buyout option that expires in 2016.
The $15 million investment will be used to advance Gamida Cell’s clinical programs, including the development of an experimental treatment for patients with high risk hematological malignancies, or blood cancers such as leukemia and lymphoma and sickle cell disease.
Gamida plans to initiate a Phase III clinical trial with NiCord in mid-2016, according to Reuters.
Novartis will not have rights or options to Gamida Cell products or technology under the terms of the agreement.
Other Gamida shareholders include Israeli firms that have been the subjects of politically motivated divestment by European business, including Elbit Imaging and Teva Pharmaceutical Industries.
Hello, fellow Forward reader! I’m Joel Brown, a Forward reader and supporter for more than 15 years, and currently the chair of the board of directors.
I’m an avid Forward reader because it ticks so many of my essential boxes: excellent journalism, Jewish focus and diverse viewpoints. In today’s political climate, what I most appreciate is the Forward’s independence — made possible by the generosity of its membership.
The Forward is committed to bringing you unbiased, nuanced Jewish news. From my position as board chair, I see an exciting future as we expand our position as the definitive independent voice of contemporary American Judaism.
That’s why I’m paying it Forward, by matching $36,000 of reader gifts. It’s an investment in the Forward’s newsroom, to continue telling the American Jewish story with truth and independence.
— Joel Brown, Forward board chair
Support our mission to tell the Jewish story fully and fairly.
